Organon (OGN) Gains from Investment Securities (2021 - 2026)

Organon's Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities changed 0.0% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at -$87.0 million (down 410.71% YoY), while the FY2025 annual figure was -$87.0 million, down 1352.16% from the prior year.
• Gains from Investment Securities was $1.0 million for Q1 2026 at Organon, up from -$27.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $41.0 million in Q4 2023 to a low of -$73.0 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged -$1.8 million across 5 years, with a median of $2.0 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities surged 720.0% in 2023, then sank 3750.0% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $5.0 million in 2022, then surged by 720.0% to $41.0 million in 2023, then tumbled by 90.24% to $4.0 million in 2024, then sank by 775.0% to -$27.0 million in 2025, then surged by 103.7% to $1.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.0 million (Q1 2026), -$27.0 million (Q4 2025), and -$73.0 million (Q3 2025), per Business Quant data.